Table 4.
Currently active clinical trials with nanocarriers for treating skin diseases.
| Type of skin disease | Type of nanocarriers | Loading drugs | Status | Phase | NCT identifier |
|---|---|---|---|---|---|
| Psoriasis vulgaris | Liposomes & ethosomes | Anthralin | Completed | Phase 4 | NCT03348462 |
| Psoriasis | MEs | MTX | Not yet recruiting | Phase 4 | NCT04971239 |
| Psoriasis | MEs | Cyclosporine A | Completed | Phase 3 | NCT00438360 |
| Lentigo maligna | Nanoemulsion | 5-aminolevulinic acid | Completed | Phase 4 | NCT02685592 |
| AD | Liposomal gel | HL-009 | Completed | Phase 2 | NCT01568489 |
| AD | MEs | DNK333 | Completed | Phase 2 | NCT01033097 |
| Radiation induced dermatitis | Liposomes | APN201 | Completed | Phase 2 | NCT01513278 |
| Actinic keratosis | Liposomes | T4N5 | Unknown | Phase 3 | NCT00002811 |
| Actinic keratosis | Nanoemulsion | BF-200 ALA (Ameluz) | Completed | Phase 3 | NCT02799069 |
| Basal cell carcinoma | Liposomes | T4N5 | Completed | Phase 2 | NCT00089180 |
Data obtained from http://www.clinicaltrials.gov.